NICE Backs New Second-Line Oral Option for CLL

Published Date: 22 Apr 2026

NICE draft guidance recommends pirtobrutinib as an at-home oral option for CLL patients who have exhausted BTK inhibitor treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radioactive ion beams successfully treat animal tumors in study

2.

A computer-aided diagnostic system for improved detection of breast cancer.

3.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

4.

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

5.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot